Squamous Cell Carcinoma Antigen Isoforms in Serum from Cervical Cancer Patients

Röijer, Eva; Bruijn, H.W.A. de; Dahlén, Ulrika; Hoor, KA Ten; Lundin, Maria; Nilsson, Karin; Söderstrom, Karin; Nilsson, Olle

doi:10.1159/000092775

Cited by 12 publications

(10 citation statements)

References 25 publications

(34 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Serum tumor markers are known to be useful tools for early detection of recurrence and in the follow-up of cancer patients, and in some cases they may also provide independent prognostic information [12]. Recent evidence revealed that expression levels of several cytokines and proteins reflect PASI scores and that those levels in serum may be useful as indicators of psoriasis severity (such as IFN-γ, IL-6, TNF-α, and IL-8) [13, 14], but these studies failed to obtain quantitatively correlative results [15].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Serum Squamous Cell Carcinoma Antigen in Psoriasis: A Potential Quantitative Biomarker for Disease Severity

et al. 2018

View full text Add to dashboard Cite

Background: An objective and quantitative method to evaluate psoriasis severity is important for practice and research in the precision care of psoriasis. Objectives: We aimed to explore serum biomarkers quantitatively in association with disease severity and treatment response in psoriasis patients, with serum squamous cell carcinoma antigen (SCCA) evaluated in this pilot study. Methods: 15 psoriasis patients were treated with adalimumab. At different visits before and after treatment, quantitative body surface area (qBSA) was obtained from standardized digital body images of the patients, and the psoriasis area severity index (PASI) was also monitored. SCCA were detected by using microparticle enzyme immunoassay. The serum biomarkers were also tested in healthy volunteers as normal controls. Receiver-operating characteristic (ROC) curve analysis was used to explore the optimal cutoff point of SCCA to differentiate mild and moderate-to-severe psoriasis. Results: The serum SCCA level in the psoriasis group was significantly higher (p < 0.05) than in the normal control group. After treatment, the serum SCCA levels were significantly decreased (p < 0.05). The SCCA level was well correlated with PASI and qBSA. In ROC analysis, when taking PASI = 10 or qBSA = 10% as the threshold, an optimal cutoff point of SCCA was found at 2.0 ng/mL with the highest Youden index. Conclusion: Serum SCCA might be a useful quantitative biomarker for psoriasis disease severity.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Serum concentrations of SCCA in squamous cell carcinoma patients are correlated with the clinical stage and the degree of histological tumor differentiation [12]. Studies have found upregulated expression of SCCA in both squamous cell carcinoma and psoriasis lesions [26], while the biological role of SCCA in psoriasis remains obscure.…”

Section: Discussionmentioning

confidence: 99%

Serum Squamous Cell Carcinoma Antigen in Psoriasis: A Potential Quantitative Biomarker for Disease Severity

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Data published so far conclude that it is not clear whether A1, A2 or both should be measured in clinical assays [7] . The clinical information gained with the Abbott assay is clearly biased towards measurement of A1.…”

Section: Discussionmentioning

confidence: 99%

Characterization of Monoclonal Antibodies Directed against Squamous Cell Carcinoma Antigens: Report of the Second TD-10 Workshop

Nustad¹,

Nilsson²,

Majnesjö³

et al. 2009

Tumor Biol

View full text Add to dashboard Cite

Eight monoclonal antibodies directed against Squamous Cell Carcinoma Antigens (A1 and A2) were collected and evaluated by three working groups. Recombinant antigens, fusion proteins and native antigens from normal tissue were used to evaluate antibody specificity. Five antibodies reacted with both A1 and A2. Two of these antibodies (K123 and K131) showed related binding characteristics, whereas SCC140, K182 and SCC111 demonstrated unique epitope specificity and were not related to the reference antibodies included (F1H3, F2H7 and SCC107). SCC111 reacted particularly well with antigen on Western blot, indicating that the epitope was partly hidden when the antigen was in solution. Two antibodies (SCC103 and SCC109) reacted only with A2 and the fusion protein A1/A2, indicating that they recognized an A2 epitope in exon 8. The A2-specific antibodies are unique in their binding to A2 and are different from the reference antibodies included (SCC104 and K122). SCC103 is probably the best A2-specific antibody available. One antibody, K136, was A1-specific and is related to reference antibody K135. The new antibodies can be used to establish immunometric assays for specific measurement of A1, A2 or both A1 and A2 together.

show abstract

“…However, discordance between detection of elevated serum tumor markers and the diagnosis was reported, and the serum tumor markers may not be elevated despite the presence of recurrent disease. 23 Bolli et al 24 reviewed charts of 272 patients followed up for cervical cancer with 1053 samples evaluated. Of the 70 patients whose conditions were diagnosed with recurrence, 81% had elevated values.…”

Section: Tumor Markersmentioning

confidence: 99%

Surveillance Procedures for Patients With Cervical Carcinoma: A Review of the Literature

Zanagnolo

Minig

Gadducci

et al. 2009

Int J Gynecol Cancer

View full text Add to dashboard Cite

Cervical cancer is still one of the most common malignancies in women. Treatment of cervical cancer is very successful, especially in the early stage. However, some patients will experience recurrence. The primary purpose of follow-up programs is early detection of recurrence disease that should be more likely to be amenable to treatment, thereby improving the clinical outcome. Although, in the literature, most studies have shown that the surveillance programs did not improve the clinical outcome of patients with diagnosis of recurrence, this clinical practice is regarded as traditional management. The use of Papanicolaou tests to detect recurrent cervical cancer is not sufficiently justified. The assessment of tumor markers such as the squamous cell carcinoma antigen could be useful. Imaging techniques are important for the detection and assessment of recurrent disease. The role of chest x-rays in detecting asymptomatic recurrence in patients treated for cervical carcinoma remains controversial. Detection of a new abnormal mass or the changes in the size of a known lesion caused by cancer growth and the determination of the extent of recurrence with computed tomography and magnetic resonance imaging may provide clinical assistance in the selection of optimal therapy. The fluoro-2-deoxy-glucose-positron emission tomography for surveillance only show 80% of specificity and accuracy with negative predictive value of 100%. Integrated fluoro-2-deoxy-glucose-positron emission tomography/computed tomography provides precise anatomic localization of suspicious areas and, therefore, a better diagnostic interpretation with a possible impact on disease-free survival as well. In conclusion, our review confirms the need for prospective studies to compare the effectiveness of different follow-up regimens measuring overall survival and quality of life parameters as outcomes.

show abstract

Squamous Cell Carcinoma Antigen Isoforms in Serum from Cervical Cancer Patients

Cited by 12 publications

References 25 publications

Serum Squamous Cell Carcinoma Antigen in Psoriasis: A Potential Quantitative Biomarker for Disease Severity

Serum Squamous Cell Carcinoma Antigen in Psoriasis: A Potential Quantitative Biomarker for Disease Severity

Characterization of Monoclonal Antibodies Directed against Squamous Cell Carcinoma Antigens: Report of the Second TD-10 Workshop

Surveillance Procedures for Patients With Cervical Carcinoma: A Review of the Literature

Contact Info

Product

Resources

About